Drugs / BGB-10188
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04282018 | Apr 2020 → Aug 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 | BeiGene | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-10188 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04282018 ↗ |
| Action | Inhibit | “BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor” NCT04282018 ↗ |
| Route | Oral | “received BGB-10188 60 milligrams (mg) orally” NCT04282018 ↗ |